Editas Medicine, Inc., a leading gene editing company, has announced the presentation of new in vivo data at the European Hematology Association 2025 Congress. The data demonstrates therapeutically relevant levels of HBG1/2 promoter editing in hematopoietic stem cells using a single dose of proprietary targeted lipid nanoparticle delivery in non-human primates. This approach, which aims to upregulate fetal hemoglobin, is in pre-clinical development for treating sickle cell disease and beta thalassemia. The results, which achieved a 58% mean editing rate at five months post-treatment, will be detailed in a poster session scheduled for June 14, 2025, at the Allianz MiCo, Milano Convention Centre. A presentation of these findings is currently available on the Editas Medicine website.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.